Arcutis Biotherapeutics

ARQT · NASDAQ

$32.82+$0.93 (+2.92%)TodayMarket closed · Oct 20, 7:37 PM ET

Prev close $31.89

ARQT analyst rating

BuyConsensus of 8 analysts over the last 12 months. 88% rate it a buy.

Strong buy0
Buy7
Hold1
Underperform0
Sell0

12-month price target · 9 analysts

Average $37.74 (+15.0% upside)

Low: $34.34
Now: $32.82
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

ARQT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Oct 19, 2026	Maintains	Buy	$38.00 → $44.00	57%
Cantor Fitzgerald	Oct 15, 2026	Initiates	Overweight	$48.00	39%
Morgan Stanley	Aug 6, 2026	Maintains	Overweight	$34.00 → $38.00	43%
Guggenheim	Aug 6, 2026	Maintains	Buy	$35.00 → $38.00	57%
Needham	Aug 6, 2026	Maintains	Buy	$36.00 → $40.00	53%
Needham	May 7, 2026	Maintains	Buy	$36.00	53%
Mizuho	Mar 2, 2026	Maintains	Outperform	$37.00 → $35.00	46%
Guggenheim	Feb 27, 2026	Maintains	Buy	$34.00 → $35.00	57%
TD Cowen	Feb 26, 2026	Maintains	Buy	$30.00 → $35.00	49%
HC Wainwright & Co.	Feb 26, 2026	Maintains	Buy	$30.00 → $34.00	50%

The case for and against

Updated Oct 17, 2026

Bull case

Arcutis Biotherapeutics is compelling because it is building a leading branded topical dermatology franchise around ZORYVE, a potent PDE4 inhibitor with differentiated 0.3% cream and foam formulations that already address plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Its commercial execution has been strong, with product net sales rising from $29M in 2023 to $167M in 2024 and $372M in 2025, while 2Q26 ZORYVE sales of $129.9M rose 59% year over year and helped support guidance of $525M–$540M for 2026. The outlook is further strengthened by limited direct competition in seborrheic dermatitis, positioning advantages versus Opzelura in atopic dermatitis, and additional upside from pediatric expansion, vitiligo, HS, and ARQ-234 pipeline readouts.

Bear case

Arcutis Biotherapeutics is viewed negatively because its Zoryve growth outlook relies on sustaining share gains in a highly competitive topical market, where generic products and recently approved Vtama can limit uptake and pressure net sales through higher gross-to-net discounts. The company also faces commercialization friction from physician demand, prior authorization-heavy payer access, and third-party dependence on Interquim for supply and manufacturing, which raises execution and supply-chain risk. On the financial side, rising operating expenses tied to commercialization and pipeline development suggest a need for additional capital, while slower-than-expected uptake, worse-than-expected GTN, and manufacturing issues could materially weaken the investment case.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.